Guía de diseño y mejora continua de procesos asistenciales integrados. 2ª ed

Publicado en la página web de la Consejería de Igualdad, Salud y Políticas Sociales: www.juntadeandalucia.es/salud (Consejería de Salud / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

Tratamiento sustitutivo de la insuficiencia renal crónica : diálisis y trasplante renal : proceso asistencial integrado 2ª ed

Proceso publicado en la página web de la Consejería de Salud: www.juntadeandalucia.es/salud (Consejería de Salud / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

Asma : proceso asistencial integrado

Este Proceso (2012) integra los dos publicados anteriormente de Asma en la edad pediátrica (2003) y Asma en la edad adulta (2004). Fichero en formato pdf, publicado en la página web de la Consejería de Salud y Bienestar Social: www.juntadeandalucia.es/salud (Consejería de Salud y Bienestar Social / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

Urolitiasis [Recurso electrónico] : proceso asistencial integrado

Fichero en formato pdf, publicado en la página web de la Consejería de Salud: www.juntadeandalucia.es/salud (Consejería de Salud / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

How Wages and Employment Adjust to Trade Liberalization: Quasi-Experimental Evidence from Austria

We study the response of regional employment and nominal wages to trade liberalization, exploiting the natural experiment provided by the opening of Central and Eastern European markets after the fall of the Iron Curtain in 1990. Using data for Austrian municipalities, we examine differential pre- and post-1990 wage and employment growth rates between regions bordering the formerly communist economies and interior regions. If the "border regions" are defined narrowly, within a band of less than 50 kilometers, we can identify statistically significant liberalization effects on both employment and wages. While wages responded earlier than employment, the employment effect over the entire adjustment period is estimated to be around three times as large as the wage effect. The implied slope of the regional labor supply curve can be replicated in an economic geography model that features obstacles to labor migration due to immobile housing and to heterogeneous locational preferences.

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

BACKGROUND Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in other EGFR-overexpressing tumors, such as those occurring in breast cancer. Although KRAS is mutated in only a minor fraction of breast tumors (5%), about 60% of the basal-like subtype express EGFR and, therefore could be targeted by EGFR inhibitors. We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a molecular basis for the evaluation of anti-EGFR therapies. METHODS Total, genomic DNA was obtained from a group of 35 formalin-fixed paraffin-embedded, triple-negative breast tumor samples. Among these, 77.1% (27/35) were defined as basal-like by immunostaining specific for the established surrogate markers cytokeratin (CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp. RESULTS We found no evidence of KRAS oncogenic mutations in all analyzed tumors. CONCLUSIONS This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases.

Role of gene methylation in antitumor immune response: Implication for tumor progression

Cancer immunosurveillance theory has emphasized the role of escape mechanisms in tumor growth. In this respect, a very important factor is the molecular characterization of the mechanisms by which tumor cells evade immune recognition and destruction. Among the many escape mechanisms identified, alterations in classical and non-classical HLA (Human Leucocyte Antigens) class I and class II expression by tumor cells are of particular interest. In addition to the importance of HLA molecules, tumor-associated antigens and accessory/co-stimulatory molecules are also involved in immune recognition. The loss of HLA class I antigen expression and of co-stimulatory molecules can occur at genetic, transcriptional and post-transcriptional levels. Epigenetic defects are involved in at least some mechanisms that preclude mounting a successful host-antitumor response involving the HLA system, tumor-associated antigens, and accessory/co-stimulatory molecules. This review summarizes our current understanding of the role of methylation in the regulation of molecules involved in the tumor immune response.

Collectio sermonum de dominicis, de festis et de sanctis, ad usum Fratrum Minorum.

« Sermo adaptabillis b. Laurentio... Dispersit, dedit pauperibus... Quia secundum b. Dionixium in De ecclesiastica Yerarchia... » (1-2) ; — « Sermo de assumptione b. Marie... Quid hoc audio de te... Quid nos tantilly... » (2v-3), suivi d'une note à l'usage des prédicateurs : « Nota quod ne sermo sit deffectuosus... » (3) ; — « Sermo de conceptione b. Marie. Que est ista que progreditur... Karissimi, predicator evangelicus, beatitudinis eterne preco... » (3v-4v) ; — « Sermo de quatuor festis principalibus b. Marie... Que est ista que progreditur... Verba ista sunt tocius curie celestis... » (4v-5v) ; — « Sermo de Purificatione. In mansuetudine suscipite... Secundum b. Gregorium, Mor. 23... » (6-7) ; — « Sermo de b. Francischo... Cujus est ymago hec et superscriptio... Secundum b. Gregorium, omelia 30... » (7v-8v) ; — « Sermo in dominica [in Quinquagesima]. Ecce ascendimus Jerosolimam... Karissimi, sicut scitis, finis est... » (9-10) ; — [Sermo in dominica IIa post Epiphaniam] « Tu servasti vinum bonum usque adhuc... In verbis istis spiritualiter intellectus... » (10-10v) ; — « Sermo de b. Francischo. Ad ymaginem similitudinis sue... Verba ista ad litteram scripta... » (11-12) ; — « Sermo de b. Johane Baptista. Magnus es tu et faciens mirabilia... Secundum Gregorium quia tute... » (12v-13) ; — « Sermo de angelis. Inmittit angelus Domini... Sanctus ille David, acceptus de ovibus... » (13v-14) ; — « In ascensione Domini. Exultavit ut gigas... Duo sunt inter cetera Christi misteria... » (14v-16) ; — « De asumpcione Domine nostre. Ad preceptum tuum elevabitur aquila... Quia, karissimi, Mater Domini... » [FRANCISCUS DE MAYRONIS] ; cf. éd. Bâle, 1498, f. CIV-CIIIV, avec variantes (16v-18) ; — « De Maria Magdalena. Permittuntur [sic pro : Remittuntur] tibi peccata tua... Sicut solent maximi principes... » [Idem], sermon abrégé ; cf. éd. cit., f. LXXXVIIIV-XCI (18-19v) ; — « De s. Johane Evangelista. Dillectus meus michi... Ostenditur b. Johannes prout inflamatus... » [Idem], résumé ; cf. éd. cit., f. XXIX-XXIXV (20) ; — « In festo apostolorum Petri et Pauli. Accepimus gratiam et apostolatum... Gloriosissimi christiane fidei religionis... » (20v-23v) ; — « Sermo de gratia divina acquirenda. Accepimus gratiam etc. Vivat, obsecro, anima mea ... quoniam... » (24) ; — « Accepimus gratiam etc. Restat ostendere via physionomica... » (24v-26) ; — « Sermo de beatitudine, sive gloria celesti, sive in festo Omnium sanctorum. Fons sapientie verbum Dei... Ecce ego sto prope fontem... In hoc festo precipue et anno... » (26-29) ; — « De nativitate Domine nostre. Egredietur virga de radice Jesse... Percutiet terram virga... Clementissimus pastor ovium... » (29v-32) ; — « Sermo de uno confessore pontifice. Rector fratrum et stabilimentum populi... Inter viros eximie sanctitatis... » (32v) ; — « De nativitate Domini. Transeamus usque Bethelem... Innocencius in quodam sermone de predicatione... » (34v-36) ; — « In die nativitatis Domini. Sol ortus est et humiles exaltati sunt... Beatus Augustinus, De Civitate Dei : Anima participacione... » (36-37v) ; — « Dominica infra octavas Nativitatis. Ecce positus est hic in ruinam... Secundum doctrinam Philosophi in diversis locis... » (38-38v) ; — « Dominica quarta in quadragesima. Sequebatur eum multitudo magna... Secundum Damascenum libro primo, capitulo XV°, diversitas actionum... » (39-40v) ; — « De Canane[a], dominica secunda [sic] in quadragesima [Feria 5a post dom. Ia in XLa]. Dimitte illam quia clamat... Si attendamus ordinem generacionis... » (41-42v) ; — « Dominica de Passione. Si veritatem dico vobis... Secundum sententiam Phylosophi primo Metaphysice... » (43-43v) ; — « In cena Domini. Hodie est rex et cras morietur... Omne agens ordinate prius inquirit... » (44-45) ; — « De resurectione. Hec dies quam fecit Dominus... Scilicet est ex dictis Philosophi in diversis locis... » (45v-47) ; — « Dominica in Quadragesima. Ecce nunc tempus acceptabile... Ut dicit Philosophus, secundo de Celo et mundo... » (47-48v) ; — « De b. Clara. Sicut lux meridiana clara est... Secundum Philosophum tertio Methaphysice, si res creatas... » (48v-49v) ; — « Sermo de Cruce. Vidit mulier quod bonum esset lignum... Sicut ex doctrina Philosophi primo Ethicorum... » (50-51) ; — « De s. Anthonio. Misit servum suum hora cene... Sicut in rebus naturalibus docet experiencia... » (51v-52v) ; — « De b. Johane Batista. Tu puer propheta Altissimi... Secundum doctrinam Hugonis in commento de angelica Jerarchia... » (53-54) ; — « De b. Bertholameo [sic]. Dedit illi contra inimicos potenciam... Racio docet et experiencia manifestat... » (54v-55) ; — « De b. Francischo. Amice, ascende superius... Dicit Philosophus quinto Physicorum quod motus... » (55v-56) ; — [De b. Bernardo] « Omnia parata sunt, venite ad nupcias... Sicut videmus in motu naturali... » (56v-57) ; — « De sacerdote novo. Vos elegit Dominus... Ut potest haberi ex dictis Dyonisii... » (57v-58v) ; — « De assumpcione Virginis gloriose. Elevetur tronus David super Israel... Videmus quod triplici racione aliqua corpora... » (58v-59v) ; — « De assumpcione Virginis. Veni de Libano sponsa mea... Secundum testimonium Scripturarum et humane consuetudinis... » (59v-61) ; — « De Trinitate. Tripliciter sol exurens montes... Secundum quod dicit Philosophus, tota nostra noticia... » (61-61v) ; — « De b. Francischo. Hic beatus in facto suo erit... Post doctrinam philosophorum et experienciam... » (62-62v) ; — [De b. Eligio] « Provideat rex virum sapientem... Secundum sententiam (secundum) sapientis primo Metaphysice . » (63-64) ; — « De resurrectione Domini. Tercia dies est hodie... Tripliciter alicujus rei non vise accipimus fidem certam... » (64-65) ; — «Stetit in medio discipulorum et dixit : Pax vobis... Ut dicit b. Augustinus undevicesimo de Civitate Dei... » (65v-67) ; — « De Omnibus sanctis... Gloriosa dicta sunt de te... Aperta est civitas... Doctore egregio Bernardo scilicet attestante... » (67-69) ; — « De b. Johane Batista. Hic venit in testimonium... Sicut potest probari ex dictis Philosophi et exemplis... » (69v-70) ; — « De b. Petro apostolo. Tu pasce populum meum Israel... Secundum sententiam Philosophi tertio Politicorum... » (70v-71) ; — « De assumpcione Virginis gloriose. Transibo in locum tabernaculi... Triplici ratione secundum philosophorum doctrinam aliqua moventur... » (71v-72v) ; — [De b. Francisco] « Adolescens, tibi dico surge... Consideranti sciderum revolucionem... » (73-74v) ; — [De s. Michaele] « Michael et angeli preliabantur... Sicut ex doctrina Phylosophi in pluribus locis patet... » (74v-76) ; — « De b. Nicholao. Petra fundebat michi rivos olei... Secundum philosophicam doctrinam, diversitas effectuum... » (76-77) ; — « In festo apostolorum Petri et Pauli. Fecit Deus duo luminaria magna... Secundum sententiam Philosophi secundo Methaphysice... » (77v-78) ; — « De b. Bertholameo. Vidi angelum fortem... Secundum dictum Philosophi, omnes transferentes... » (78v-79) ; — « Dominica in Quadragesima. Ductus est Jhesus in desertum... Sicut naturalium operationum multiplex experiencia... » (79v-80v) ; — « De s. Thoma apostolo. Ecce cognovi quoniam Deus meus es... Bernardus in sermone : Deus noverim me... » (81-81v) ; — « De sacerdote novo. Misit Dominus servum suum... Secundum quod dicit Philosophus primo Ethicorum, diversarum operationum... » (82-82bis) ; — « In purificatione Virginis. Parasti ante faciem omnium populorum... Si attendamus formationem rerum temporalium... » (82bisv-83v) ; — « De uno martire. Esto vir fortis, et prelia bella Domini... Secundum consuetudinem hominum... » (84-85) ; — « De festo Purificacionis. Lucerna splendens super candelabrum... Doctrina philosophorum et tradit... » (85v-86v) ; — « Feria quarta Cinerum. Cum jejunas unge caput tuum... Morum Philosophi doctrinam perlegens et attendens... » (87-88v) ; — « In quarta feria Cinerum. Cum jejunatis, nolite fieri sicut ypocrite... Sicut ex doctrina Philosophi primo Ethicorum potest colligi... » (88v-89v) ; — « In festo b. Lodovici [episcopi]. Surrexit rex de solio suo... Ut dicit Philosophus quarto Methaphysicorum... » (90-91v) ; — « De b. Jacobo. Vox tonitrui tui in rota... Secundum doctrinam philosophicam formarum naturalium... » (91v-92v) ; — [In festo Annunciationis] « Ecce concipies in utero... Secundum doctrinam Philosophi septimo de Animalibus, ad generationem... » (93-94) ; — « De s. Ludovico [episcopo]. Reposita est michi corona justitie... Secundum sententiam Philosophi secundo Phisicorum, omne agens... » (94-96).

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

BACKGROUND In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. METHODOLOGY/PRINCIPAL FINDINGS KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p=0.0038; HR: 1.40; 95% CI:1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p=0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p=0.0054; OR: 1.77; 95% CI: 1.18-2.64). CONCLUSIONS/SIGNIFICANCE This analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses.

Insuficiencia cardíaca : proceso asistencial integrado 2ª ed

Publicado en la página web de la Consejería de Igualdad, Salud y Políticas Sociales: www.juntadeandalucia.es/salud (Consejería de Igualdad, Salud y Políticas Sociales/ Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

Analysis of c-Myc function in mouse epidermis

Abstract The c-myc gene is one of the most frequently mutated oncogenes found in human tumors. c-Myc has been implicated in the regulation of various biological processes including cell cycle progression, cellular growth, differentiation, angiogenesis, immortalization and apoptosis. To assess the normal role of c-Myc in epithelial cell types in vitro and in vivo we have deleted the c-myc gene in keratinocytes and in the adult skin epidermis by conditional Cre/loxP mediated recombination. Similar to what we have previously shown in mouse embryonic fibroblasts acute elimination of c-Myc activity in cultured keratinocytes causes cells to cease proliferation and adapt a flat cell morphology. Mutant cells accumulate in a diploid Ki67neg stage, indicative of a quiescent Go stage. This demonstrates that c-Myc activity is essential to maintain keratinocytes in a productive cell cycle. In addition, mutant keratinocytes showed a defect in Ca2+ induced induction of the differentiation marker Keratin 1 suggesting a role for c-Myc during differentiation. To assess the in vivo role of c-Myc we used a tamoxifen inducible K5::CreERT transgene to delete the c-myc gene in the adult skin epidermis. Unexpectedly, despite strong c-Myc expression in the basal compartment it is not required for maintenance of the skin epidermis in the adult mouse. The epidermis appeared normal with respect to both proliferation and differentiation. In addition, no selection against c-Myc deficient epidermal cells occurred over many months, further confirming that c-Myc is dispensable for normal skin homeostasis. Even more surprising, TPA induced hyperproliferation also occurred in a c-Myc independent manner. Treatment of the skin with the mutagen DMBA prior to TPA is a classical way to induce papillomas by selecting for mutations that lead to dominant activation of the oncogene Ha-Ras. Most interestingly tumor formation was severely inhibited suggesting that tumor progression requires endogenous c-Myc. Further studies are required to address whether the role of c-Myc in the activation of telomerase or the Werner protein, or its role to induce angiogenesis is required for skin tumor progression, In conclusion, this work shows that while c-Myc is not required for maintenance or hyperplasia of mouse epidermis, it is essential for skin tumor progression in collaboration with Ras. Résumé Le gène c-myc est un des oncogènes les plus fréquemment mutés dans les tumeurs humaines. c-Myc est impliqué dans la régulation de processus biologiques variés, comme la progression du cycle cellulaire, la croissance cellulaire, la différenciation, l'angiogenèse, l'immortalisation et l'apoptose. Pour caractériser le rôle physiologique de c-Myc dans les cellules de type épithélial in vitro et in vivo, le gène c-myc a été délété dans des kératinocytes primaires et dans l'épiderme de peau de souris adultes par des recombinaisons conditionnelles (système Cre/loxP). De la même façon que dans les fibroblastes d'embryon de souris, l'élimination aiguë de l'activité de c-Myc dans les kératinocytes en culture primaire provoque l'arrêt de la prolifération des cellules et leur applatissement morphologique. Les cellules mutantes restent dans un stade diploïde Ki67neg, indiquant un stade quiescent Go. Cela démontre que l'activité de c-Myc est essentielle pour maintenir les kératinocytes dans le cycle cellulaire. De plus, les kératinocytes mutants montrent une déficience pour le marqueur de différenciation Kératine 1 au cours de la différenciation induite par le calcium, suggérant un rôle de c-Myc dans la différenciation cellulaire. Pour comprendre le rôle de c-Myc in vivo, le transgène K5::CreERT inductible par le tamoxifen a été utilisé pour déléter le gène c-inyc dans l'épiderme de souris adultes. Etonnemment, malgré une forte expression de c-Myc dans le compartiment basal de l'épiderme, ce gène n'est pas nécessaire pour la maintenance de l'épiderme de la peau chez la souris adulte. L'épiderme apparait normal avec une prolifération et une différenciation physiologique des cellules. De plus, il n'y a pas de sélection contre les cellules épidennales c-Myc déficientes après plusieurs mois, ce qui confirme que c-Myc n'est pas nécessaire pour l'homéostasie normale de la peau. Encore plus surprenant, une hyperprolifération est également induite par du TPA chez les souris mutantes, impliquant une voie de prolifération indépendante de c-Myc. Le traitement de la peau par le mutagène DMBA avant le traitement au TPA est une voie classique d'induction de papillomes, par sélection de mutations conduisant à l'activation de l'oncogène Ha-Ras. La formation des tumeurs est fortement inhibée chez les souris mutantes, suggérant que la progression des tumeurs nécessite la présence endogène de c-Myc. De nouvelles études sont nécessaires pour savoir si c-Myc a un rôle dans l'activation de la télomérase ou de la protéine de Werner, ou encore dans l'angiogénèse, qui sont nécessaires pour la progression tumorale. En conclusion, ce travail montre que même si c-Myc n'est pas nécessaire pour la maintenance ou l'hyperplasie de la peau de souris, il est essentiel pour la progression des tumeurs de la peau en collaboration avec Ras.